The antiaggregating activity of clopidogrel is not affected by N-acetyl L-cysteine

Summary

N-acetyl L-cysteine (NAC) is widely used to treat obstructive bronchopulmonary diseases. It has thiol reactive properties, accounting for its mucolytic activity. Clopidogrel is a potent antithrombotic compound, metabolised by the liver which generates an active metabolite containing a thiol reactive group, responsible for an irreversible interaction with the platelet P2Y₁₂ADP receptor.

The aim of this study was to determine if NAC interferes with the antiaggregating activity of clopidogrel. For this purpose, NAC (100 µM) was incubated with platelets from rats treated or not with clopidogrel (5 mg/kg, PO, -2 h). Clopidogrel treatment strongly inhibited aggregation but this effect was not modified by NAC. In another experiment, a low concentration of the active metabolite of clopidogrel (0.3 µg/ml) was incubated with platelets from men or rats, in the absence or presence of NAC (100 µM). When stimulated by ADP (2.5 µM), platelet aggregation was inhibited by the active metabolite when incubated alone. In the presence of NAC, the inhibition by the active metabolite was not modified, therefore clearly indicating that NAC cannot reduce the thiol reactive part of the active metabolite of clopidogrel and does not interfere with its anti-aggregating activity. Moreover, in rats treated for 5 days with NAC (150 mg/kg), the activity of clopidogrel (5 or 10 mg/kg) against ADP-induced platelet aggregation was neither inhibited nor increased. This demonstrates that the generation of the active metabolite of clopidogrel is not affected by NAC.

In conclusion, we have found that NAC does not restore the “normal” properties of P2Y₁₂on platelets from clopidogrel-treated animals, it does not interfere with the antiaggregating activity of the active metabolite of clopidogrel, and does not interfere with the generation of the active metabolite.

Keywords

Clopidogrel - N-acetyl L-cysteine - aggregation - platelets

• References

• 1 CAPRIE Steering Committee, a randomized, blinded, trial of SR25990C versus aspirin in patients at risk of ischaemic events (CAPRIE) Lancet 1996; 348: 1329-39.
• 2 Mehta SR, Yusuf S, Peters RJ. et al Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-33.
• 3 Savi P, Herbert JM, Pflieger AM. et al Importance of hepatic metabolism in the anti-aggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol 1992; 44: 527-32.
• 4 Savi P, Pereillo JM, Uzabiaga MF. et al Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000; 84: 891-6.
• 5 Savi P, Labouret C, Delesque N. et al P2Y₁₂, a new platelet ADP receptor, target of clopidogrel. Biochem Biophys Res Commun 2001; 283: 379-83.
• 6 Easton JD. Clinical aspects of the use of clopidogrel, a new antiplatelet agent. Semin Thromb Hemost 1999; 25 Suppl 2: 77-82.
• 7 Havranek EP, Weinberger J. Concomitant use of angiotensin-converting enzyme (ACE) inhibitors and antiplatelet therapies: clopidogrel versus aspirin. J Hypertens 1999; 17: S57
• 8 Bhatt DL, Foody JAM, Hirsch AT. et al Complementary, additive benefit of clopidogrel and lipid-lowering therapy in patients with atherosclerosis. J Am Coll Cardiol 2000; 35 (02) Suppl A 326A.
• 9 Lidell C, Svedberg LE, Lindell P. et al Absence of interaction between clopidogrel and warfarin in patients on long-term anticoagulation. J Am Coll Cardiol 2001; 37 (02) (Suppl A) 314A
• 10 Slugg PH, Much DR, Smith WB. et al Cirrhosis does not affect the pharmacokinetics and pharmacodynamics of clopidogrel. J Clin Pharmacol 2000; 40: 396-401.
• 11 Plavix, European Public Assessement Report, Summary of product characteristics. The European Agency of the Evaluation of Medical Products. EMEA Website, http://www.emea.eu.int.
• 12 Bernard GR. N-acetylcysteine in experimental and clinical acute lung injury. Am J Med 1991; 91 (03) 54S-59S.
• 13 Lewis RK, Paloucek FP. Assessment and treatment of acetaminophen overdose. Clin Pharm 1991; 10: 765-74.
• 14 Villani F, Galimberti M, Monti E. et al Effect of glutathione and N-acetylcysteine on in vitro and in vivo cardiac toxicity of doxorubicin. Free Radic Res Commun 1990; 11: 145-51.
• 15 Cotgreave IA, Moldeus P. Lung protection by thiol-containing antioxidants. Bull Eur Physiopathol Respir 1987; 23: 275-7.
• 16 Ruffmann R, Wendel A. GSH rescue by N-acetylcysteine. Klin Wochenschr 1991; 69: 857-62.
• 17 Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature (Lond) 1962; 194: 927-9.
• 18 Anfossi G, Russo I, Massucco P. et al N-ace-tyl-L-cysteine exerts direct anti-aggregating effect on human platelets. Eur J Clin Invest 2001; 31: 452-61.
• 19 Murakami S, Mori Y. Changes in the structure of rat mucous glycoprotein and prostaglandin cytoprotection. J Pharmacobiodyn 1986; 9: 760-70.
• 20 Loscalzo J. N-Acetylcysteine potentiates inhibition of platelet aggregation by nitroglycerin. J Clin Invest 1985; 76: 703-8.
• 21 Savi P, Combalbert J, Gaich C. et al The anti-aggregating activity of clopidogrel is due to a metabolic activation by hepatic cytochrome P450-1A. Thromb Haemostas 1994; 72: 313-7.
• 22 Pereillo JM, Andrieu A, Maftouh M. et al Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos 2002; 30: 1288-95.
• 23 Cesarone CF, Romano M, Serra D. et al Effects of aminothiols in 2-acetylaminofluorene-treated rats. II. Glutathione cycle and liver cytosolic activities. In Vivo 1987; 1: 93-9.
• 24 Elfarra AA. Potential role of the flavin-containing monooxygenases in the metabolism of endogenous compounds. Chem Biol Interact 1995; 96: 47-55.